Mint Tower Capital Management B.V. Purchases Shares of 38,043 Surmodics, Inc. (NASDAQ:SRDX)

Mint Tower Capital Management B.V. acquired a new position in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 38,043 shares of the company's stock, valued at approximately $1,507,000. Mint Tower Capital Management B.V. owned about 0.27% of Surmodics at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Modus Advisors LLC acquired a new position in Surmodics during the 4th quarter valued at about $40,000. Quest Partners LLC increased its stake in shares of Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company's stock valued at $42,000 after acquiring an additional 1,071 shares during the period. R Squared Ltd bought a new stake in Surmodics during the fourth quarter worth approximately $55,000. SG Americas Securities LLC boosted its stake in Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock valued at $275,000 after purchasing an additional 1,255 shares in the last quarter. Finally, Algert Global LLC increased its position in shares of Surmodics by 29.9% during the 3rd quarter. Algert Global LLC now owns 17,820 shares of the company's stock valued at $691,000 after purchasing an additional 4,098 shares during the period. 96.63% of the stock is currently owned by institutional investors.

Surmodics Stock Performance

Shares of NASDAQ:SRDX traded up $0.16 during trading on Monday, reaching $30.91. The stock had a trading volume of 32,269 shares, compared to its average volume of 278,358. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The stock has a fifty day simple moving average of $32.87 and a two-hundred day simple moving average of $36.73. The firm has a market capitalization of $441.89 million, a price-to-earnings ratio of -30.60 and a beta of 1.19. Surmodics, Inc. has a 52 week low of $25.17 and a 52 week high of $42.44.

Remove Ads

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. As a group, analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on SRDX. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Thursday, January 30th. StockNews.com initiated coverage on Surmodics in a research note on Monday, February 3rd. They set a "hold" rating for the company. Finally, Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a research report on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $50.00.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).